Project description:Our study provides compelling support to an effective CAR-T cell anti-aging intervention using NMN, a key NAD+ intermediate. We found the clinical potential of NMN for CAR-T cell immunotherapy for human cancers, attributed to their central memory phenotype. The cells are more viable, proliferative, and long-lived in vivo. Furthermore, these CAR-T cells exerted great antitumor efficacy against tumors in human xenograft mouse models. Detailed molecular mechanisms responsible for the pleiotropic effects of NMN need to be investigated further. So RNA-seq was used to analyze the different gene expression of these CAR-T cells.

2023-04-01 | GSE200367 | GEO

CD19-CAR-T Cells Bearing a KIR/PD-1-Based Inhibitory CAR Eradicate CD19+HLA-C1- Malignant B Cells While Sparing CD19+HLA-C1+ Healthy B Cells.

Project description: Not available

| S-EPMC7564565 | biostudies-literature

Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity.

Project description: Not available

| S-EPMC2561922 | biostudies-literature

A safe and potent anti-CD19 CAR T cell therapy.

Project description: Not available

| S-EPMC7518381 | biostudies-literature

Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines.

Project description: Not available